<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037295</url>
  </required_header>
  <id_info>
    <org_study_id>999914045</org_study_id>
    <secondary_id>14-DK-N045</secondary_id>
    <nct_id>NCT02037295</nct_id>
  </id_info>
  <brief_title>Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans</brief_title>
  <official_title>Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to study both stool and urine energy loss in 24 individuals on two experimental&#xD;
      diets (50% increased and 50% reduced nutrient load relative to body size) in a random&#xD;
      cross-over design. Following this over/underfeeding, volunteers will also be randomly&#xD;
      assigned to a placebo versus oral antibiotic medication arm. This study will extend our&#xD;
      previous findings by investigating whether 1) nutrient absorption changes upon similar&#xD;
      increases/decreases in relative nutrient load and 2) whether manipulation of gut microbial&#xD;
      communities with antibiotics alters nutrient absorption and 3) how these changes may affect&#xD;
      glucose tolerance and fat storage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obesity has risen to epidemic proportions in the world, resulting from both&#xD;
      excessive energy intake and low levels of energy expenditure. The effect of nutrient&#xD;
      absorption on energy balance, that is, the relative amount of nutrients consumed vs. the&#xD;
      amount excreted in stool, has been reported only in small studies in which energy waste in&#xD;
      feces and urine between lean and obese individuals was not found to be different. New studies&#xD;
      have shown that bacteria in the gut may play an important role in calorie absorption. We have&#xD;
      recently shown that leaner individuals absorbed more calories when overfed compared to when&#xD;
      they were given a diet with just enough calories to maintain their own weight. Our studies&#xD;
      have also found that overfeeding also changes the kinds of bacteria found in the gut. In lean&#xD;
      individuals, these changes in gut bacterial communities with overfeeding were associated with&#xD;
      changes in how many calories were absorbed. Our results are similar to those seen in other&#xD;
      studies in animals and humans that suggest a role for gut bacteria in weight gain and&#xD;
      obesity. To try to better understand the role of gut bacteria in absorbing food, we propose&#xD;
      to investigate 1) whether energy loss (as measured in stool and urine) changes following&#xD;
      over- and underfeeding relative to body size and 2) whether changes in the gut bacteria,&#xD;
      induced by an antibiotic medication, affect nutrient absorption and glucose tolerance. We&#xD;
      plan to study 24 healthy non-smoking volunteers age 18 45 years old, not taking any&#xD;
      medications (including medications for weight loss, antibiotics or probiotics) for the&#xD;
      examination. All participants will be admitted to the Clinical Research Unit for 31 days.&#xD;
      During their stay, subjects will be fed a weight maintaining diet for 3 days, followed by two&#xD;
      experimental diets (150% and 50% of weight maintaining calories) in a random order. After&#xD;
      this, volunteers will be randomly assigned to one of two groups: group 1 will take oral&#xD;
      antibiotic medication; group 2 will receive pills that look the same but will not contain any&#xD;
      active medication (placebos). Feces (stool) will be collected throughout the study.&#xD;
      Additionally, twenty four-hour urine collections will take place each day of the experimental&#xD;
      diet period and when stool is collected on the antibiotics. The energy content of these waste&#xD;
      products as well as that of the diet (using duplicate plate analysis) will be measured by&#xD;
      bomb calorimetry. Bacterial components in feces will be extracted by repeated fractional&#xD;
      centrifugation to obtain bacterial mass and by using 16S rDNA-based oligonucleotide probes to&#xD;
      obtain data on gut bacteria. Primary results will examine how many calories remain in stool&#xD;
      during relative over- and underfeeding and whether changes in gut bacteria, induced by an&#xD;
      antibiotic medication, affect nutrient absorption and glucose tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 14, 2014</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool Calories During OF and UF</measure>
    <time_frame>Days 5-7 and 11-13</time_frame>
    <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool Calories During Vancomycin and Placebo</measure>
    <time_frame>Days 23-25</time_frame>
    <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Calories During OF and UF</measure>
    <time_frame>Days 5-7 and 11-13</time_frame>
    <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Calories During Vancomycin and Placebo</measure>
    <time_frame>Days 23-25</time_frame>
    <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2 Hour Glucose Tolerance From Day 16 to Day 28 During Vancomycin and Placebo</measure>
    <time_frame>Day 16 and day 28</time_frame>
    <description>A 75-g 2 hour oral glucose tolerance test (OGTT) was performed on days 16 and 28, before and after treatment with vancomycin or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Gut Microbial Colonization During OF and UF</measure>
    <time_frame>Days 5-7 and 11-13</time_frame>
    <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Gut Microbial Colonization During Vancomycin and Placebo</measure>
    <time_frame>Days 23-25</time_frame>
    <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>OF_UF Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OF_UF Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UF_OF Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UF_OF Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 125mg orally four times per day for 12 days</description>
    <arm_group_label>OF_UF Vancomycin</arm_group_label>
    <arm_group_label>UF_OF Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo pills orally four times per day for 12 days</description>
    <arm_group_label>OF_UF Placebo</arm_group_label>
    <arm_group_label>UF_OF Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Overfeeding diet (OF)</intervention_name>
    <description>Diet in which the calories are 150% of their weight maintaining energy requirements</description>
    <arm_group_label>OF_UF Placebo</arm_group_label>
    <arm_group_label>OF_UF Vancomycin</arm_group_label>
    <arm_group_label>UF_OF Placebo</arm_group_label>
    <arm_group_label>UF_OF Vancomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Underfeeding diet (UF)</intervention_name>
    <description>Diet in which the calories are 50% of their weight maintaining energy requirements</description>
    <arm_group_label>OF_UF Placebo</arm_group_label>
    <arm_group_label>OF_UF Vancomycin</arm_group_label>
    <arm_group_label>UF_OF Placebo</arm_group_label>
    <arm_group_label>UF_OF Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Free of acute and chronic diseases (especially GI disorders) as determined by medical&#xD;
        history, physical examination and laboratory tests.&#xD;
&#xD;
        Individuals may be taking laxative drugs but they must be discontinued 3 or more weeks&#xD;
        before admission.&#xD;
&#xD;
        Age 18-45 y (in order to minimize the affect of aging on nutrient absorption).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Because it is unclear how chronic illnesses or substance abuse could affect nutrient&#xD;
        absorption we will exclude volunteers with chronic diseases or current substance abuse.&#xD;
        This is especially important because the limited number of study subjects in this study&#xD;
        will make it hard to control for these confounders. We will therefore exclude subjects with&#xD;
        a history or clinical manifestation of:&#xD;
&#xD;
          -  Current smoking&#xD;
&#xD;
          -  Type 2 diabetes (according to the World Health Organization diagnostic criteria)&#xD;
&#xD;
          -  Endocrine disorders, such as Cushing s disease, pituitary disorders, and hypo- and&#xD;
             hyperthyroidism&#xD;
&#xD;
          -  HIV infection (self-report), due to effects on weight and body composition of HIV and&#xD;
             medications used to treat HIV&#xD;
&#xD;
          -  Active tuberculosis (self-report)&#xD;
&#xD;
          -  Asthma on active daily treatment with medications&#xD;
&#xD;
          -  Pulmonary disorders including physician diagnosed chronic obstructive pulmonary&#xD;
             diseases and obstructive sleep apnea syndrome&#xD;
&#xD;
          -  Cardiovascular diseases, including coronary heart disease, heart failure, arrhythmias,&#xD;
             and peripheral artery disease&#xD;
&#xD;
          -  Hypertension (according to the World Health Organization diagnostic criteria), treated&#xD;
             or uncontrolled&#xD;
&#xD;
          -  Gastrointestinal disease, including inflammatory bowel diseases (e.g. Crohn s disease&#xD;
             and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer&#xD;
             (active) and irritable bowel syndrome.&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Anemia (defined as hemoglobin &lt; 11 mg/dl), leucopenia (defined as white blood cell&#xD;
             count &lt; 4,000/microL) or thrombocytopenia (defined as platelet count &lt; 150,000/microL)&#xD;
&#xD;
          -  Liver disease, including non-alcoholic fatty liver disease or current elevated liver&#xD;
             enzymes over 1.5 times the normal range for AST, ALT or GGT or a history and physical&#xD;
             exam that indicates a potential liver disease as describe by Giannini et al&#xD;
&#xD;
          -  Evidence of chronic renal disease as defined by estimated glomerular filtration rate&#xD;
             of &lt; 60 ml/min or evidence of overt proteinuria on urine dipstick.&#xD;
&#xD;
          -  Central nervous system disease, including previous history of cerebrovascular&#xD;
             accidents, dementia, and neurodegenerative disorders&#xD;
&#xD;
          -  Cancer requiring treatment in the past five years, except for non-melanoma skin&#xD;
             cancers or cancers that have clearly been cured or in the opinion of the investigator&#xD;
             carry an excellent prognosis&#xD;
&#xD;
          -  Behavioral or psychiatric conditions that would be incompatible with a safe and&#xD;
             successful participation in the study (such as major depression, schizophrenia and&#xD;
             presence of psychotic symptoms)&#xD;
&#xD;
          -  Eating disorders such as anorexia nervosa, bulimia or binge eating syndrome&#xD;
&#xD;
          -  Taking weight loss drugs&#xD;
&#xD;
          -  Weight change of more than 5% of total body weight in the 3 months before admission&#xD;
&#xD;
          -  Use of any antibiotic or probiotic agents within 6 months prior to minimize the&#xD;
             potential effects of these substances on the gut microbiota.&#xD;
&#xD;
          -  Use of antacids (Proton pump inhibitors, H2 antagonists or aluminum/magnesium&#xD;
             hydroxide) 3 months prior to the study assessed by self-report because a modified&#xD;
             gastric pH might affect the gut microbiota as well&#xD;
&#xD;
          -  Evidence of alcohol and/or drug abuse (more than 3 drinks per day and use of drugs,&#xD;
             such as amphetamines, cocaine, heroin, or marijuana)&#xD;
&#xD;
        The following exclusion criteria are necessary because of the substances given or tests&#xD;
        performed during the study&#xD;
&#xD;
          -  Known allergies to vancomycin&#xD;
&#xD;
          -  Known allergies to heparin or a history of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Personal history or evidence of a bleeding disorder&#xD;
&#xD;
        All individuals will be fully informed of the aim, nature, and risks of the study prior to&#xD;
        giving written informed consent. The study s informed consent will be obtained by a&#xD;
        principal or associate investigator, research physician or physician assistant working in&#xD;
        the clinical research unit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Krakoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIDDK, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002 Feb 21;346(8):591-602. Review.</citation>
    <PMID>11856799</PMID>
  </reference>
  <reference>
    <citation>Weststrate JA, Dekker J, Stoel M, Begheijn L, Deurenberg P, Hautvast JG. Resting energy expenditure in women: impact of obesity and body-fat distribution. Metabolism. 1990 Jan;39(1):11-7.</citation>
    <PMID>2294371</PMID>
  </reference>
  <reference>
    <citation>Segal KR, Dunaif A. Resting metabolic rate and postprandial thermogenesis in polycystic ovarian syndrome. Int J Obes. 1990 Jul;14(7):559-67.</citation>
    <PMID>2228390</PMID>
  </reference>
  <results_reference>
    <citation>Basolo A, Hohenadel M, Ang QY, Piaggi P, Heinitz S, Walter M, Walter P, Parrington S, Trinidad DD, von Schwartzenberg RJ, Turnbaugh PJ, Krakoff J. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nat Med. 2020 Apr;26(4):589-598. doi: 10.1038/s41591-020-0801-z. Epub 2020 Mar 23.</citation>
    <PMID>32235930</PMID>
  </results_reference>
  <verification_date>March 29, 2019</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <results_first_submitted>May 27, 2020</results_first_submitted>
  <results_first_submitted_qc>July 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut Microbiota</keyword>
  <keyword>Obesity</keyword>
  <keyword>Absorption</keyword>
  <keyword>Overfeeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02037295/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OF_UF Vancomycin</title>
          <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="P2">
          <title>OF_UF Placebo</title>
          <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="P3">
          <title>UF_OF Vancomycin</title>
          <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="P4">
          <title>UF_OF Placebo</title>
          <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: Crossover UF and OF</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2: Vancomycin and Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OF_UF Vancomycin</title>
          <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="B2">
          <title>OF_UF Placebo</title>
          <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="B3">
          <title>UF_OF Vancomycin</title>
          <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="B4">
          <title>UF_OF Placebo</title>
          <description>Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="13.3"/>
                    <measurement group_id="B2" value="34.9" spread="7.2"/>
                    <measurement group_id="B3" value="29.7" spread="4.4"/>
                    <measurement group_id="B4" value="38.4" spread="3.6"/>
                    <measurement group_id="B5" value="35.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stool Calories During OF and UF</title>
        <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day)</description>
        <time_frame>Days 5-7 and 11-13</time_frame>
        <population>4 subjects were excluded from the analysis because the delineation of the diet periods using two dye markers was not clear</population>
        <group_list>
          <group group_id="O1">
            <title>Overfeeding</title>
            <description>Healthy volunteers assigned overfeeding diet&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Underfeeding</title>
            <description>Healthy volunteers assigned underfeeding diet&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Calories During OF and UF</title>
          <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day)</description>
          <population>4 subjects were excluded from the analysis because the delineation of the diet periods using two dye markers was not clear</population>
          <units>percentage of calorie intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.9"/>
                    <measurement group_id="O2" value="8.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stool Calories During Vancomycin and Placebo</title>
        <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
        <time_frame>Days 23-25</time_frame>
        <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had missing stool data</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Calories During Vancomycin and Placebo</title>
          <description>Calculated as stool calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
          <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had missing stool data</population>
          <units>percentage of calorie intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.9"/>
                    <measurement group_id="O2" value="5.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Calories During OF and UF</title>
        <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day)</description>
        <time_frame>Days 5-7 and 11-13</time_frame>
        <population>4 subjects were excluded from the analysis because the delineation of the diet periods using two dye markers was not clear</population>
        <group_list>
          <group group_id="O1">
            <title>Overfeeding</title>
            <description>Healthy volunteers assigned overfeeding diet&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Underfeeding</title>
            <description>Healthy volunteers assigned underfeeding diet&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Calories During OF and UF</title>
          <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day)</description>
          <population>4 subjects were excluded from the analysis because the delineation of the diet periods using two dye markers was not clear</population>
          <units>percentage of calorie intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Calories During Vancomycin and Placebo</title>
        <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
        <time_frame>Days 23-25</time_frame>
        <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had missing stool data</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Calories During Vancomycin and Placebo</title>
          <description>Calculated as urine calories (kcal/day) x 100/ingested calories (kcal/day), vancomycin compared to placebo</description>
          <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had missing stool data</population>
          <units>percentage of calorie intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.3"/>
                    <measurement group_id="O2" value="1.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 2 Hour Glucose Tolerance From Day 16 to Day 28 During Vancomycin and Placebo</title>
        <description>A 75-g 2 hour oral glucose tolerance test (OGTT) was performed on days 16 and 28, before and after treatment with vancomycin or placebo.</description>
        <time_frame>Day 16 and day 28</time_frame>
        <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had a missing OGTT.</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin&#xD;
Vancomycin: Vancomycin 125mg orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo&#xD;
Placebo oral tablet: Placebo pills orally four times per day for 12 days&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 2 Hour Glucose Tolerance From Day 16 to Day 28 During Vancomycin and Placebo</title>
          <description>A 75-g 2 hour oral glucose tolerance test (OGTT) was performed on days 16 and 28, before and after treatment with vancomycin or placebo.</description>
          <population>Phase 2: Of the 27 participants enrolled, 2 participants dropped out and 1 had a missing OGTT.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="16.8"/>
                    <measurement group_id="O2" value="-1.9" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Gut Microbial Colonization During OF and UF</title>
        <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
        <time_frame>Days 5-7 and 11-13</time_frame>
        <population>Data were available during both diets for only 15 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Overfeeding</title>
            <description>Healthy volunteers assigned overfeeding diet&#xD;
Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Underfeeding</title>
            <description>Healthy volunteers assigned underfeeding diet&#xD;
Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Gut Microbial Colonization During OF and UF</title>
          <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
          <population>Data were available during both diets for only 15 subjects</population>
          <units>log 10 copies per gram weight</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.39" lower_limit="9.21" upper_limit="9.98"/>
                    <measurement group_id="O2" value="9.73" lower_limit="9.32" upper_limit="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Gut Microbial Colonization During Vancomycin and Placebo</title>
        <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
        <time_frame>Days 23-25</time_frame>
        <population>Data were available for only 23 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin Vancomycin: Vancomycin 125mg orally four times per day for 12 days Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo Placebo oral tablet: Placebo pills orally four times per day for 12 days Overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements Underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Gut Microbial Colonization During Vancomycin and Placebo</title>
          <description>qPCR-based quantification of 16S rRNA gene copies per gram wet weight (log10)</description>
          <population>Data were available for only 23 subjects</population>
          <units>log 10 copies per gram weight</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" lower_limit="9.41" upper_limit="10.14"/>
                    <measurement group_id="O2" value="9.42" lower_limit="9.07" upper_limit="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 31 days</time_frame>
      <desc>All adverse events, including those observed by or reported to the research team, will be recorded. Serious unanticipated problems, Unanticipated Adverse Device Effects and serious protocol deviations, will be reported to the IRB and Clinical Director (CD) as soon as possible but not more than 7 days after the PI first learns of the event. Not serious unanticipated problems will be reported to the IRB and CD as soon as possible but not more than 14 days after the PI first learns of the event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overfeeding</title>
          <description>Healthy volunteers assigned overfeeding diet (OF): Diet in which the calories are 150% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="E2">
          <title>Underfeeding</title>
          <description>Healthy volunteers assigned underfeeding diet (UF): Diet in which the calories are 50% of their weight maintaining energy requirements</description>
        </group>
        <group group_id="E3">
          <title>Vancomycin</title>
          <description>Healthy volunteers assigned Vancomycin: Vancomycin 125mg orally four times per day for 12 days</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Healthy volunteers assigned Placebo oral tablet: Placebo pills orally four times per day for 12 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Krakoff, M.D.</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</organization>
      <phone>(602) 200-5217</phone>
      <email>jkrakoff@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

